Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × IT-101 × Clear all
NCT01625936 2018-08-29

CRLX101 Plus Bevacizumab in Advanced RCC

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
22 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡